Sylentis, part of PharmaMar Group, secured a €21.1M NextGenerationEU grant for its Syoligo project—Spain’s first RNA drug production plant. Located in Getafe, Madrid, it will focus...
PharmaMar started February with falls of almost 3% at the opening of the market. The reason was that Sylentis had failed in its primary objective of...
Sylentis is preparing for a new trial. The study has been approved by the FDA in 30 days and will be part of the marketing authorization...